
Happy alone Qiagen changes course after Thermo Fisher offers to buy it in $11.5B deal
Dutch diagnostics company Qiagen — which is developing tests for the ongoing coronavirus epidemic — is being acquired by US-based scientific instruments maker Thermo Fisher Scientific in a deal valued at $11.5 billion, including debt.
The announcement comes months after the Netherlands-based company, which is listed on the NYSE, notified investors that it was reviewing potential strategic alternatives after it received several “indications of interest” for an acquisition. But by December, it concluded it would prefer to go it alone.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.